IMAGEENS Raises 1.2Mn€ Seed Financing Round to Launch Its First Two Products
15.4.2021 12:41:00 EEST | Business Wire | Press release
IMAGEENS, a Paris-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, has secured 1.2Mn€ in seed financing. The round was led by Anaxago, with a participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing IMAGEENS investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005466/en/
IMAGEENS' software solutions allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to better assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
The funding will allow IMAGEENS to accelerate the development and commercialization of ArtFun+, an artificial intelligence software and its prognostic biomarkers for cardiovascular imaging, and LABEL, an algorithmic solution for the automatic classification and valorization of medical imaging data. It will also allow to strengthen its team with key R&D talents and build its commercial team to scale the deployment of its software solutions.
"We are delighted to have been able to quickly complete this round table in collaboration with ANAXAGO. We will be able to announce the launch of several strategic projects as well as key hires in the coming months, which will be the cornerstones of IMAGEENS' development over the next few years," said Robert Baldwin, CEO of IMAGEENS.
ArtFun+ stems from the US National Institute of Health (NIH)-funded Multi-Ethnic Study of Atherosclerosis (MESA) which studied the prognostic power of imaging biomarkers on a multi-ethnic cohort of 3675 patients across the United States. In the study, the imaging biomarkers of ArtFun+ were shown to be highly predictive of death and hard cardiovascular for patients between 45 and 84 years old. Beyond the MESA trial, the imaging biomarkers of ArtFun+ were studied in 77 scientific publications and used in 31 leading clinical centers around the globe.
Today, IMAGEENS is in the process of obtaining FDA and CE-clearance for ArtFun+ in routine cardiovascular care to complement to cardiac MRI exams with cardiovascular risk biomarkers enabling improved follow-up and surgical decisions in ischemic cardiopathies, acute coronary syndrome, and aortic aneurysms.
Since late 2020, IMAGEENS has also developed a complementary business to its diagnostic solutions, by helping Europe’s largest medical data warehouses improve the quality of their medical data and use it for R&D and AI-training purposes. By working with leading medical institutions such as the AP-HP in Paris, IMAGEENS has developed a comprehensive set of image classification algorithms that automatically create metadata allowing the data warehouses to get a detailed understanding of the databases’ content, and the ability to precisely query the medical data to setup cohorts for R&D and AI-training projects.
ABOUT IMAGEENS
Founded in 2017, IMAGEENS develops software solutions for doctors to leverage the full potential of advanced medical imaging data. IMAGEENS commercializes two products: ArtFun+, an innovative software to calculate vascular stiffness and flow imaging biomarkers that are predictive of patients’ long-term risk of death and hard cardiovascular events, and LABEL, a set of image classification algorithms that enable large medical data warehouses to precisely query and create data cohorts for R&D and AI-training projects.
ABOUT ANAXAGO
Created in 2012, the Anaxago group is the first 100% digital private neo-bank, accessible to the greatest number of people, combining impact and performance. With more than 100,000 members, 250 companies and real estate projects financed since its creation and more than 250 million euros collected, Anaxago stands out for the selectivity and the support of the investment projects proposed on its platform. Anaxago is an independent group, majority owned by its founders, and currently has 40 employees. The investment in IMAGEENS was led by Alex Heraud and Gaston Vasseur. Anaxago counsels: M Guilain Hippolyte, Reed Smith LLP.
www.anaxago.com
ABOUT BADGE
Created in 2004 Les Business Angels des Grandes Ecoles is one of the largest networks of Business Angels in France. The mission is to support the development of emerging innovative projects with high growth potential. Since 2005 BADGE has financed 188 projects with 38 M€, having generated a total financing of more than 100 M€.
www.business-angels.info
ABOUT COALESCENCE
Coalescence is a network of Business Angels sharing the same values; they wish to promote the growth of young innovative projects. Beyond finance the members of Coalescence bring kind support with their various professional background.
www.coalescence.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005466/en/
Contact information
Press Contact:
IMAGEENS: press@imageens.com
Website: www.imageens.com
Anaxago: gaston@anaxago.com
Press Agency:
Annie-Florence Loyer
afloyer@newcap.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
One in Three Western Consumers Now Buy Products Discovered on Social Platforms as AI Reshapes Commerce, According to NIQ26.6.2026 11:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today revealed new analysis presented at The Consumer Goods Forum (CGF) Global Summit showing that nearly one in three consumers in Western markets now purchase products they first discover on social platforms, as artificial intelligence (AI) and emerging commerce models accelerate a shift toward discovery-led commerce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626970024/en/ Presented by Emilie Darolles, President, West Europe, NIQ, the findings highlight a fundamental shift in how consumers discover, evaluate, and purchase products—blurring traditional geographic, channel, and operational boundaries. New growth engine: commerce models scaling from East to West NIQ’s latest global insights show that live, social, and quick commerce models—long scaled across Asia—are now a significant driver of incremental digital growth globally, as these formats expand rapidl
SureWerx ® Acquires Genesi S.r.l.26.6.2026 11:00:00 EEST | Press release
SureWerx®, a leading global provider of safety, tool & equipment products, announced today that it has acquired Genesi S.r.l. Terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626881708/en/ Based in Bergamo, Italy, Genesi is a leading provider of safety solutions for work-at-height and confined space solutions. For more than 20 years, Genesi has built its reputation on a customer-centered approach, combining innovative, high-quality products with engineering expertise, training, services, maintenance and after-sales support to help protect workers in high-risk environments. Its portfolio includes fall protection systems, horizontal and vertical lifelines, anchor points, guardrails, ladders, access solutions, and confined space safety systems. Guided by the belief that there is no protection without knowledge, Genesi is committed to advancing safety culture and helping workers return home safely ever
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom